Medicure Inc. (CVE:MPH – Get Free Report) hit a new 52-week high on Tuesday. The company traded as high as C$2.84 and last traded at C$2.84, with a volume of 400 shares changing hands. The stock had previously closed at C$2.72.
Medicure Stock Performance
The firm has a 50 day simple moving average of C$1.92 and a 200 day simple moving average of C$1.42. The company has a current ratio of 0.97, a quick ratio of 1.28 and a debt-to-equity ratio of 6.02. The firm has a market capitalization of C$29.64 million, a PE ratio of -3.94 and a beta of 0.93.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
See Also
- Five stocks we like better than Medicure
- Anthropic’s IPO Could Put Amazon’s and Alphabet’s Paper Profits to the Test
- Microsoft’s AI Spending Didn’t Change—Wall Street’s View of It Did
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
- L3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
